<bill session="115" type="h" number="2889" updated="2019-04-18T16:11:14Z">
  <state datetime="2017-06-13">REFERRED</state>
  <status>
    <introduced datetime="2017-06-13"/>
  </status>
  <introduced datetime="2017-06-13"/>
  <titles>
    <title type="official" as="introduced">To amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title.</title>
    <title type="short" as="introduced">Closing Loopholes for Orphan Drugs Act</title>
    <title type="short" as="introduced">Closing Loopholes for Orphan Drugs Act</title>
    <title type="display">Closing Loopholes for Orphan Drugs Act</title>
  </titles>
  <sponsor bioguide_id="W000800"/>
  <cosponsors>
    <cosponsor bioguide_id="H001045" joined="2017-06-13"/>
    <cosponsor bioguide_id="P000258" joined="2017-06-21"/>
    <cosponsor bioguide_id="V000108" joined="2018-12-12"/>
  </cosponsors>
  <actions>
    <action datetime="2017-06-13">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-06-13" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2017-06-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Drug therapy"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2017-06-13T04:00:00Z" status="Introduced in House">Closing Loopholes for Orphan Drugs Act

This bill amends the Public Health Service Act to revise the 340B Drug Pricing Program, which currently requires drug manufacturers to discount orphan drugs (drugs for rare conditions) for certain entities covered by the program. The bill discounts orphan drugs that are not being used to treat rare conditions for all entities covered by the program.</summary>
  <committee-reports/>
</bill>
